Tianchen's Minimally Invasive Glaucoma Drainage System Achieves Pioneering Implantation at Beijing Tongren Hospital, Boosting Domestic Substitution

A landmark breakthrough has recently emerged in the ophthalmic medical field. Tianchen Runmu (Suzhou) Biotech Co., Ltd. ("Tianchen") successfully completed the first clinical implantation of its independently developed Minimally Invasive Glaucoma Drainage System (GDT) at Beijing Tongren Hospital. This historic milestone not only opens a new pathway for domestic highquality treatment optis for glaucoma patients but also marks a significant leap forward in China's(selfinnovation) capabilities for glaucoma therapeutics, substantially accelerating the domestic substitution of imported medical devices.

【Accurate implementation of surgery with immediate results】

The GDT implantation, performed by Chief Physician Jia Hongyan from the Glaucoma Department of Beijing Tongren Hospital, Capital Medical University, successfully treated a complex glaucoma case. Preoperative intraocular pressure (IOP) averaged 23.5mmHg, posing significant ocular risks. PostGDT implantation, IOP dropped to 7mmHg on Day 1 and stabilized at 10mmHg with discontinued glaucoma medications at oneweek followup, demonstrating zero complications. This milestone solidifies GDT's clinical viability and underscores its transformative potential in glaucoma management.

【Innovation driven, GDT products have unique advantages】

As a pioneering developer of highprecision ophthalmic devices, Tianchen assembles multidisciplinary experts in materials science, optics, and clinical ophthalmology to address unmet clinical needs. Its minimally invasive glaucoma drainage tube, implanted via a corneal microincision, establishes a novel aqueous humor drainage pathway for sustained intraocular pressure control. Engineered for longterm stability and safety, this innovation delivers targeted, effective glaucoma treatmen

【Adapt to demand and deeply cultivate the field of glaucoma treatment】

Glaucoma, the leading irreversible blinding disease globally, threatens vision health with rising prevalence in China. Current estimates indicate tens of millions of Chinese patients, a figure growing amid population aging and modern lifestyle pressures. Traditional glaucoma surgeries face challenges like trauma, slow recovery, and complications.

Tianchen's GDT system, leveraging MIGS (Minimally Invasive Glaucoma Surgery), revolutionizes treatment through microincision implantation. This approach minimizes tissue damage, enables rapid recovery, and mitigates structural risks inherent to conventional methods. Suitable for earlystage patients and those hesitant about traditional surgery, MIGS delivers personalized care with superior efficacy, advancing gla

【Diversified layout, building a matrix of ophthalmic medical products】

Tianchen's exploration and innovation in the field of ophthalmic medical devices have not stopped at the GDT system. In response to other common ophthalmic diseases such as myopia and dry eye, the company actively expands its research and development path and successfully launches multiple innovative and combined product lines. Among them, the fast selling series products for dry eye syndrome closely meet the daily care needs of patients. Starting from the root cause of dry eye syndrome, they emphasize the importance of home care and daily health care, and tailor more intimate, practical, and effective treatment plans for patients. The successive emergence and widespread application of these diversified products have further optimized the company's product line layout, comprehensively consolidated its leading position in the field of ophthalmic medical devices, and laid a solid foundation for the company's long-term development.

【Success in the first planting, ushering in a new journey for domestic ophthalmology】

The first successful implantation of Tianchen GDT system in Beijing Tongren Hospital is not only a strong affirmation of the company's longterm focus on research and development and pursuit of excellence, but also an important symbol of the qualitative leap in China's glaucoma medical device technology level. This achievement is expected to break the longterm technological monopoly of similar foreign products in the field of glaucoma treatment, injecting strong impetus into the rise of the domestic ophthalmic medical device industry. With the gradual promotion, popularization, and indepth application of GDT system, more and more glaucoma patients will benefit from it and regain their confidence in eye health and life。

Looking ahead to the future, Tianchen will steadfastly uphold the concept of innovation driven development, continuously increase research and development investment, and fully launch more highend ophthalmic medical devices with independent intellectual property rights, contributing more wisdom and strength to the vigorous development of China's ophthalmic medical industry. We are full of expectations and believe that in the near future, domestic ophthalmic medical devices will emerge on the global ophthalmic medical market with their excellent quality and innovative strength, shining brightly and bringing more bright welfare and hope for cure to ophthalmic patients worldwide, writing a new chapter in the development of China's ophthalmic medical industry.